Thu, May 23, 2013, 9:13 PM EDT - U.S. Markets closed
Take that with a possible FDA approval and you've got $4.50 per share price target!
March 8th is not too far away
We are now actively preparing for a meeting with the FDA as part of our plans to initiate the Phase III trial by year-end," said Steven W. King, president and chief executive officer of Peregrine. See you at $4.50 people.
This is going to have a short squeeze tommorow morning people!
Only knowledgeable investors appy.